Category Archives: Cf

referee blows his whistle for full-time. Full-time score: CF Mounana 3-5 SuperSport United

90+3 GOAAAL! Brockie grabs his brace and makes it 5-3 for SuperSport!

90+2 GOAAAL! Autchanga grabs another one for Mounana with a cool finish!

3 minutes of added time to be played

89 corner kick for SuperSport

85 corner kick for Mounana

83 free kick for SuperSport and a yellow card for Kemba

82 corner kick for Mounana

80 GOAAAL! Sinayoko makes pulls another one back for Mounana from the penalty spot!

79 PENALTY for Mounana after Ritchie is adjudged to have handled the ball inside the penalty area

76 corner kick for Mounana

75 Lakay beats his marker, but his shot goes wide of goals

68 Substitution for Mounana: Nic Sanda Zamble Yavo comes on for Makuntima

66 corner kick for Mounana and it leads to another one

64 GOAAAL! Brockie makes it 4-1 for SuperSport with a tap in from Lakay cross!

59 Substitution for SuperSport: Phala makes way for Mandla Masango

58 Guedegbes header goes over the crossbar

55 Pieterse pulls off another good save to deny Ondo

51 offside call goes against Mounana

49 Autchangas shot is saved by Pieterse from the penalty spot

48 PENALTY for Mounana after Daniels was judged to have handled the ball inside the penalty area

Mounana get the second half underway

Double substitution for SuperSport: Morgan Gould and Jeremy Gould come on for Mashamaite and Grobler respectively

Substitution for Mounana: Mazowa makes way for Corbin Guedegbe

referee blows his whistle for the half-time break. Half-time score: CF Mounana 1-3 SuperSport United

1 minute of added time to be played

44 corner kick for Mounana

41 GOAAAL! Mnyamane grabs his brace with a powerful shot!

40 free kick for SuperSport in a good area

39 offside call goes against Mounana

34 GOAAAL! Mnyamane retains SuperSports lead with a brilliant solo run!

30 Lakays shot is saved by Bitseki Moto

26 GOAAAL! Atchabao grabs the equaliser for Mounana with a tap in!

24 free kick for Mounana and a yellow card for Kekana

23 Ondo Biyoghe unleashes a powerful shot, but it goes wide of goals

20 corner kick for Mounana

19 Autchangas shot is saved by Pieterse

15 offside call goes against Mounana

11 corner kick for Mounana

9 Kekana shoots wide of goals from long range

5 GOAAAL! Poor defending by Mounana and Kekana punishes them!

4 another corner kick for SuperSport

3 corner kick for SuperSport

SuperSport get the game underway

kickoff

Starting XI:

CF Mounana XI: Moto, Makuntima, Coulibaly, Kemba, Biyoghe, Mazowa, Bamba, Biyeme, Atchabao, Autchanga, Mboudou SuperSport United XI: Pieterse, Kekana, Daniels, Mashamaite, Ritchie, Morton, Modiba, Phala, Mnyamane, Grobler, Lakay

Hello and welcome to Phakaaathis live reporting of the Caf Confederation Cup group match between CF Mounana and SuperSport United at Stade DAngondje in Libreville.

Read more here:

Blow by blow: CF Mounana vs SuperSport United | The Citizen - Citizen

Markets Daily

Why Investors remained confident on Washington Prime Group Inc. (WPG), CF Industries Holdings, Inc. (CF)? StockNewsJournal CF Industries Holdings, Inc. (NYSE:CF), maintained return on investment for the last twelve months at -1.91, higher than what Reuters data shows regarding industry's average. The average of this ratio is 9.43 for the industry and sector's best figure ... Why Should Investors Reconsider Washington Prime Group Inc. (WPG) And CF Industries Holdings, Inc. (CF)?AllStockNews all 43 news articles »

Read the rest here:

Why Investors remained confident on Washington Prime Group Inc. (WPG), CF Industries Holdings, Inc. (CF)? - StockNewsJournal

Markets Daily

CF Industries Holdings, Inc. (CF) Can't Hide When Its Chart Setup Can't Lie NY Stock News CF Industries Holdings, Inc. (CF) is looking very interesting as a trading opportunity right now. The technical setup offers the best window into what traders can expect whether they are bullish on the play or bearish. We're therefore exploring these ... Cognizant Technology Solutions Corporation - CTSH - Stock Price Today - ZacksZacks all 95 news articles »

Original post:

CF Industries Holdings, Inc. (CF) Can't Hide When Its Chart Setup Can't Lie - NY Stock News

Vinicius Jr., who plays for Flamengo in the Brazilian league and is dubbed as the next Neymar, is on his way to Real Madrid C.F., say reports

Brazilian football club Flamengos wonderkid Vinicius Junior is set to join Spanish supergiants Real Madrid C.F., according to reports in the Brazilian media.

It is being widely reported that the 16-year-old forward has reached an agreement with Real and the announcement will be made next week, en.as.com reported citing media reports.

The Brazil U-17 starlet is expected to join Real for a fee of 45 million euros ($50.4 million).

Dubbed as the next Neymar, Vinicius has been the standout young player at Flamengo since bursting into the scene with the under-13 side.

In March 2017, Junior helped Brazil win the Under-17 South American Championship, scoring 7 goals and being named the tournaments best player.

Go here to see the original:

Latest Brazilian wonderkid Vinicius Jr. set to join Real Madrid CF: Reports - Hindustan Times

Markets Daily

Which insiders are trading CF Industries Holdings, Inc. (NYSE:CF)? Post Analyst CF Industries Holdings, Inc. (NYSE:CF) reached 43.78% versus a 1-year low price of $20.77. The stock was last seen 4.2% higher, reaching at $28.56 on Friday, May 19, 2017. At recent session, the prices were hovering between $27.55 and $28.93. CF Industries Holdings, Inc. (CF) Stock Rating Reaffirmed by Barclays PLCThe Cerbat Gem CF Industries Holdings' (CF) "Equal Weight" Rating Reaffirmed at Barclays PLCSports Perspectives The CF Industries Holdings, Inc. (CF) Position Boosted by State Treasurer State of MichiganBangaloreWeekly NY Stock News -Transcript Daily all 85 news articles »

See the original post:

Which insiders are trading CF Industries Holdings, Inc. (NYSE:CF)? - Post Analyst

CAMBRIA They didnt put lipstick on a pig, but someone puckered up and kissed one anyway.

Timothy Raymond, who serves as both the early childhood through fifth grade principal and superintendent for the Cambria-Friesland School District, offered up the porcine peck during a school assembly Friday.

The smooch marked the end of the schools reading initiative, launched in December. The school challenged early childhood through fifth grade students to read more than 500,000 minutes before May 17.

Raymond opened the ceremony by sharing the story behind the initiative.

We asked what would it take to get you Cambria-Friesland Elementary students to read more than you ever have before? Raymond said.

He teased the students by saying they considered money, which earned cheers, or candy, which drew an even louder reaction. He cited school budget limitations and high dentist bills for the decision to make him kissing a pig the prize.

Raymond thanked the school staff and the public library for helping track all the minutes provided on weekly reading logs.

Raymond asked third grade teacher Scott Wotruba to open the envelope and reveal the reading minute totals for each class, offering reactions like Not there yet! or Still short as the grade totals were announced.

I dont think that you are adding correctly, Mr. Raymond, Wotruba said.

The total?

Students read 516,981 minutes, which brought eighth grade student Rylee Prochnow into the assembly, cradling a piglet in her arms. Raymond delivered on his promise to the students by laying a smack on the piglets snout.

I am so proud of you, Raymond said to the students. I would kiss a pig 500,000 more times to see you read and grow and learn.

Go here to see the original:

CF principal puckers for pig - Beaver Dam Daily Citizen

Toronto Blue Jays center fielder Kevin Pillar was suspended two games Thursday for yelling an anti-gay slur at a Braves pitcher.

The Blue Jays suspended Pillar without pay shortly after he apologized in a statement, saying he was "completely and utterly embarrassed" by the word he directed at Jason Motte.

Pillar was angry at Motte for allegedly quick-pitching him to get a strikeout that ended the seventh inning in Atlanta's 8-4 victory Wednesday night .

Replays appeared to show Pillar using the slur as he shouted toward the mound. After what he described as a sleepless night, the player acknowledged his wrongdoing.

"I regret saying it," Pillar told reporters at SunTrust Park a few hours before the finale of a four-game series against the Braves. "I'm going to use myself as an example of how there are words out there you can't use. It's not a word I use ever. ... It's something that just came out."

Toronto general manager Ross Atkins flew to Atlanta to apologize on behalf of the organization and announce the suspension, which he said was deemed appropriate by Major League Baseball and Commissioner Rob Manfred.

Pillar will miss Thursday's game against the Braves, as well as Friday's game at Baltimore. He will forfeit approximately $6,066 of his $555,000 salary, with the money donated to charity.

Pillar will also pay an undisclosed fine.

"A large group decided that was appropriate," Atkins said. "There is no question that was in the heat of the moment, but that's no excuse."

In his statement, Pillar lamented that he "helped extend the use of a word that has no place in baseball, in sports or anywhere in society today. I'm completely and utterly embarrassed and feel horrible to have put the fans, my teammates and the Blue Jays organization in this position."

The incident occurred during the Blue Jays' third straight loss to the Braves. With his team trailing 8-3, Pillar struck out swinging to end a 1-2-3 seventh. He yelled toward the mound, prompting Motte to throw up his arms as if he didn't know what the problem was.

Atlanta catcher Kurt Suzuki and home plate umpire Brian O'Nora stepped in to diffuse the tension. Pillar headed toward the outfield and the Braves left the field.

Afterward, Pillar conceded to reporters that he was frustrated by his team's struggles, though he didn't mention what he said.

"It just stems from a little frustration in myself, just the way this series has been going," he said. "It was immature, stupid. It was uncalled for. It's part of the game. I'm a competitive guy."

Pillar was much more contrite on Thursday. He called Motte to apologize, and said in his statement that he also wanted to "apologize to the Braves organization and their fans, and most importantly, to the LGBTQ community for the lack of respect I displayed last night. This is not who I am and will use this as an opportunity to better myself."

"I will be an example of how words can offend a lot of people," Pillar told reporters. "I hope people see this as just an error in judgment."

In 2012, the Blue Jays gave shortstop Yunel Escobar a three-game suspension after he played a game with an anti-gay slur written in Spanish on his eye-black stickers.

The team took a similar position toward Pillar.

"We wanted to make sure we were as proactive as possible to get in front of it," Atkins said.

Pillar's slur came during a heated game in which Braves star Freddie Freeman was struck on the left wrist by a pitch, resulting in a fracture that will sideline one of the game's best hitters for approximately 10 weeks.

In the eighth inning, both teams charged onto the field after Toronto's Jose Bautista homered off Eric O'Flaherty, stared down the Atlanta reliever and flipped his bat high in the air. Jace Peterson shouted something at Bautista as he rounded first base, and Suzuki exchanged words with the Blue Jays slugger after he touched home plate.

No punches were thrown, but O'Flaherty issued a harsh rebuke to Bautista after the game.

"That's something making the game tough to watch," the pitcher said, referring to previous home run celebrations by the Toronto slugger. "It's turned into look-at-me stuff. He hit a home run with (the Braves holding) a five-run lead and throws the bat around. I'm just tired of it. I've seen it from him enough."

AP Sports Writer Charles Odum in Atlanta, AP Baseball Writer Ronald Blum in New York and Associated Press writer Rob Gillies in Toronto contributed to this report.

Follow Paul Newberry on Twitter at http://www.twitter.com/pnewberry1963 . His work can be found at http://bigstory.ap.org/content/paul-newberry .

For more AP baseball coverage: https://apnews.com/tag/MLBbaseball

Original post:

Toronto CF Kevin Pillar suspended 2 games for anti-gay slur - ABC News

NY Stock News

CF Industries Holdings, Inc. (CF) And Its Technicals Provide Timely Picture NY Stock News The technicals for CF Industries Holdings, Inc. (CF) has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup. Making successful trades ... and more »

Read the rest here:

CF Industries Holdings, Inc. (CF) And Its Technicals Provide Timely Picture - NY Stock News

NextGen Crowdfunding is out with some data on the status of Title III Regulation Crowdfunding or Reg CF. NextGen has a tracking application that follows all past and active Reg CF offers. According to their numbers, over $37 million has been raised since the securities exemption kicked in on May 16, 2016. This total includes approximately $4 million in investor commitments for active campaigns that have reached their minimum funding goal. Total Reg CF offers stand at 142 individual campaigns with 113 having successfully closed.The average amount raised under Reg CF that have ended and met their funding goals was about $285,000.

Reg CF currently has a cap of $1,070,000. Until recently the cap was $1 million. There are multiple campaigns that have raised the maximum amount, including:

The first year of Title III data shows that investment crowdfunding is a viable option for many entrepreneurs, startups and small business owners, said NextGen Crowdfunding CEO and Founder Aubrey Chernick. Since launching a year ago with only a handful of campaigns, the industry has seen tremendous growth with commitments continuing to rise each quarter.

Dr. Richard Swart, Chief Strategy Officer of NextGen, said there had been an uptick in activity in both March and April of this year.

[This] suggests that platforms are getting better at helping companies launch. Costs for issuers are also declining, meaning that attorneys and accountants are figuring out more cost effective models to help these firms. These are very positive signs for any company looking to use Title III, explained Swart.

Reg CF allows smaller companies to raise money online from anyone (not just accredited investors). Companies may list offers via FINRA approved crowdfunding portals or Broker-Dealers. This securities exemption, along with Title II (Reg D 506c) and Title IV (Reg A+) of the JOBS Act of 2o12, ushered in a new era of leveraging the internet to connect companies in need of growth funding with investors online.

. Bookmark the

.

Read the rest here:

NextGen Crowdfunding: Title III, Reg CF Crowdfunding Exceeds $37 ... - Crowdfund Insider

ATLANTA, GA--(Marketwired - May 17, 2017) - Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare pulmonary diseases, announced today the full enrollment of its phase 2b clinical trial testing its flagship anti-inflammatory drug candidate, once-daily oral acebilustat, in adult CF patients (NCT02443688). The study is investigating the potential of acebilustat to reduce lung inflammation and preserve lung function over the course of 48 weeks in CF patients at a high risk for rapid lung function decline. Lung inflammation is still the leading cause of excessive morbidity and premature mortality associated with CF and there are no drugs approved for the treatment of CF lung inflammation. Topline results are expected in mid-2018.

In total, 200 CF patients of all CFTR genotypes across North America and Europe have been enrolled for 48 weeks of treatment comparing 50 mg and 100 mg doses of once-daily oral acebilustat against placebo. In this trial, acebilustat or placebo are being given concomitantly with standard CF care, including CFTR modulator therapies (Orkambi or Kalydeco). In addition to investigating the effect of acebilustat on lung function (FEV1 percent predicted, a standard efficacy readout for CF trials), this trial will also assess the effect of acebilustat on pulmonary exacerbations and patient reported outcomes.

"This acebilustat phase 2b trial has the potential to take the next crucial step in transforming the way we treat underlying pulmonary inflammation in CF patients, which is not currently adequately addressed, even by the best available care today," said Steven Rowe, M.D., Professor of Medicine and the Director of the Cystic Fibrosis Research Center at the University of Alabama at Birmingham, the US Principal Investigator for the study.

The design of this trial enables evaluation of outcomes stratified by patient baseline FEV1 percent predicted, number of pulmonary exacerbations experienced in the year prior to enrollment, and whether the patient is taking concomitant CFTR modulators. The study will also assess inflammation biomarkers closely tied to acebilustat's immunomodulatory mechanism of action, including sputum neutrophil elastase and serum C-reactive protein. Reductions in these inflammatory markers were observed in an earlier trial of once-daily oral acebilustat in CF patients. "If acebilustat exhibits adequate safety and beneficial effects in preserving lung function, the outcome of this trial could herald the coming of a new era for anti-inflammatory treatment of CF patients, one which could change CF patient treatment standards moving forward," said Greg Duncan, Celtaxsys CEO. "The efforts of all the investigators, site staff, and, in particular, the patients enrolled in the study are highly appreciated."

This trial has been made possible by financial and operational support from Cystic Fibrosis Foundation (CFF) Therapeutics, the CFF's nonprofit drug discovery and development affiliate focused on advancing novel therapies for CF patients.

About Cystic Fibrosis: Cystic fibrosis (CF) is a life-threatening disease that affects the lung and digestive system of 70,000 patients worldwide. CF is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene leading to abnormal CFTR protein functioning, which causes excessively high levels of thick mucus to accumulate in the lungs. Thickened mucus clogs the lungs and serves as a perfect environment to catalyze persistent bacterial colonization of the lungs. Chronic bacterial colonization of the lungs in turn elicits an excessive neutrophil driven inflammatory immune response with the overabundance of neutrophils in the lungs further compromising a patient's breathing capacity. Somewhat paradoxically, excessive production of a neutrophil byproduct, neutrophil elastase, leads to reduced bacterial clearance. Most importantly, elastase is the key driver of irreversible damage to the lungs. Over time, this cycle of infection and inflammation leads to lung function decline and increased pulmonary exacerbations. Lung inflammation is still the leading cause of morbidity and mortality associated with CF leading the CF Foundation to identify development of safe and effective anti-inflammatory therapies as a key research priority. For more information about CF, visit: http://www.cff.org.

About acebilustat (formerly CTX-4430): Acebilustat is a once-daily oral immunomodulatory drug candidate being tested for the treatment of inflammatory diseases. It is a novel small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the key enzyme in the production of the potent inflammatory mediator Leukotriene B4 (LTB4). LTA4H and LTB4 have been strongly implicated in the pathogenesis of many diseases involving inflammation, including cystic fibrosis. Acebilustat is presently being evaluated in a CF phase 2b lung function preservation trial, which is supported by the CF Foundation. This trial is assessing acebilustat's potential to preserve CF patient breathing capacity by enhancing airway clearance and reducing the irreversible damage associated with an overactivated neutrophil driven inflammatory immune response.

About Celtaxsys: Celtaxsys, Inc. is a privately-held pharmaceutical discovery and development company focused on advancing medicine to treat patients suffering from rare, orphan designated diseases. The company is developing a sustainable pipeline of first-in-class anti-inflammatory immunomodulators, including its flagship compound, acebilustat (formerly CTX-4430). Our platform of follow-on candidates are covered separately under new intellectual property and exhibit differentiated properties that enable optimization of treatment for other inflammatory diseases. For more information, please visit: http://www.celtaxsys.com.

See the article here:

Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of ... - Markets Insider